|
 |
| CASE REPORT |
|
| Year : 2021 | Volume
: 15
| Issue : 4 | Page : 457-459 |
|
|
Myasthenia gravis and COVID-19 – A clinical checkmate
Vijayalakshmi Sivapurapu, Pratheeba Natarajan, Ravindra Raghuveera Bhat, R Remadevi
Department of Anaesthesiology and Critical Care, Indira Gandhi Medical College and Research Institute, Puducherry, India
| Date of Submission | 20-Oct-2021 |
| Date of Acceptance | 24-Jan-2022 |
| Date of Web Publication | 08-Mar-2022 |
Correspondence Address:
Dr. Vijayalakshmi Sivapurapu
Plot No 7 and 8, Ground Floor, Logu Nagar, Gorimedu, Puducherry - 605 006
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/aer.aer_129_21
 Abstract | | |
Myasthenia gravis (MG) patients with coronavirus disease (COVID-19) pose a unique challenge for intensive care management. Higher risk of infection is observed in patients with MG due to the immunosuppressant medications they are prescribed. The underlying component of respiratory muscle weakness predisposes these patients to experience a more severe form of illness. In the case of diagnosis of COVID-19 in MG patients, judicious continuation of immunosuppressants, avoiding drugs that worsen MG along with the continuation of cholinesterase inhibitors is prudent. Early diagnosis in cases with high-index of suspicion, extra precautions, COVID-appropriate behavior, and early immunization is paramount for the health of MG patients during this pandemic. Keywords: COVID-19, immunosuppressive agents, myasthenia gravis
How to cite this article:
Sivapurapu V, Natarajan P, Bhat RR, Remadevi R. Myasthenia gravis and COVID-19 – A clinical checkmate. Anesth Essays Res 2021;15:457-9 |
| Introduction | |  |
Myasthenia gravis (MG) is an autoimmune disease affecting the neuromuscular junction, causing fluctuating muscle weakness, respiratory insufficiency, and may lead to life-threatening symptoms. There is difficulty in determining as to which causes more respiratory weakness – COVID-19 or MG.[1] MG patients might have preexisting respiratory muscle weakness and hence vulnerable to develop a more severe form of disease.[2],[3] COVID-19 affecting people with MG is a unique challenge as most of these patients are on immunosuppressants.[4]
We report two cases of MG from our COVID-designated hospital in South India.
| Case Reports | | |
Case one
A 67-years-old male patient had a history of breathlessness and myalgia. He was diagnosed COVID-19-positive by nasopharyngeal swab polymerase chain reaction (PCR) reverse transcription-PCR (RT PCR) test. His computed tomography (CT) thorax revealed features of mild COVID pneumonia apart from mild cardiomegaly and mediastinal adenopathy. He was a known case of systemic hypertension, coronary artery disease (CAD), MG for 15 years, postthymectomy and was on pyridostigmine 60 mg Q 8 h, antihypertensives, and oral anticoagulants. He was not vaccinated. He was prescribed azithromycin 500 mg once a day elsewhere, which he took for 3 days before admission. He initially maintained saturation of 96% with 8 L. min − 1 oxygen by face mask. We had started him on steroids, anticoagulants, and remdesivir, apart from continuing all his other medications. His echocardiogram done was unremarkable. Arterial blood gases showed Type-1 respiratory failure pattern. On the 3rd day in the intensive care unit (ICU), he desaturated and was started on noninvasive ventilation (NIV). His D-dimer levels were elevated and was started on heparin infusion. His condition improved initially and he was maintaining on intermittent NIV and nonrebreathing mask. His progress over the next few days was very gradual, but by the end of the 2nd week, he required continuous NIV. He developed dysphagia, and hence his medication was converted to equivalent parenteral dose intravenous neostigmine 0.5 mg Q 6 h was administered in place of pyridostigmine. The patient's attenders were not willing for invasive ventilation and the patient was continued on NIV, explaining the risks. On the 17th day of admission, he sustained myocardial infarction (MI) and succumbed.
Case two
An 82-years-old male patient had a history of fever, cough, and breathlessness and was diagnosed to be COVID-19-positive by RT-PCR test. He was a known case of MG for 7 years, systemic hypertension, and CAD. He was on immunosuppressant azathioprine 50 mg Q 12 h, pyridostigmine 60 mg Q 6 h, antihypertensives, and oral anticoagulants. He had taken his 1st dose of vaccine. His CT thorax revealed severe COVID pneumonia pattern. He was maintaining good oxygen saturation of 97% with 6 L. min − 1 oxygen by face mask. He received azithromycin 500 mg once a day for 5 days before admission. He was continued on all his medications, except azithromycin. His oxygen levels dropped on day 5 after admission and he was connected to NIV, on which he improved transiently but later succumbed to MI.
| Discussion | | |
Viral infections trigger autoimmunity by increasing T-cell signaling, leading to a proinflammatory environment. COVID-19 and MG, both can cause cytokine dysregulation increasing proinflammatory cytokines affecting organ systems.[5]
Immunosuppressant use may lead to higher risk of acquiring more severe COVID-19, but there is also contrary evidence regarding their protective role in reducing immune response and preventing inflammatory cytokine storm.[6] Case two was continued on azathioprine, but still, his clinical course deteriorated. Hence, close monitoring of such patients is recommended during the COVID-19 pandemic and the use of corticosteroids and immunosuppressants should be decided based on their clinical status.[5] Corticosteroid dosage may be increased, as done with the infection steroid protocols. In severe infection with sepsis, it is recommended to pause immunosuppression temporarily. Cholinesterase inhibitors do not increase the risk of infection and should not be discontinued.[4] We had continued both patients on pyridostigmine. If dysphagia develops, the oral pyridostigmine dose should be converted to the equivalent parenteral dose of neostigmine, with close monitoring for adequacy of dosage based on symptoms.[7]
Drugs such as macrolides are known to potentially worsen MG. Azithromycin blocks neuromuscular transmission at the presynaptic level and is contraindicated in MG patients.[8] Both our patients received azithromycin before reaching our ICU, and probably would have been one of the causes of worsening of symptoms in them.
Intravenous immunoglobulin (IVIG) acts by blocking cytokine production. This causes a decrease in endogenous and exogenous immunoglobulin G which leads to reduced acetylcholine receptor antibodies, neutralization of autoantibodies by anti-idiotypic antibodies, and culminating in inhibition of complement activation. IVIG is recommended to be continued for those who are already on it, but starting IVIG should be reserved only for those with acute exacerbation of MG.[4] Thrombotic complications with IVIG may be high in critically ill COVID-19 patients.[9] We did not administer IVIG fearing its immunosuppressive and thromboembolic complications.
Therefore, all MG patients with new-onset neuromuscular weakness or with underlying known disorder should be evaluated for COVID-19 during the pandemic. Close monitoring of respiratory function indicating worsening of MG is recommended in all moderate-to-high-risk patients.[5] Prolonged COVID-19 disease duration in these patients is a possibility due to inappropriate immune response in patients with autoimmune diseases.[10] Comorbid conditions of MG patients play a crucial role on the outcome. Both patients had CAD and systemic hypertension, which could have contributed to their deterioration and negative outcome. When respiratory weakness is encountered, it may be difficult to determine whether COVID-19 or MG or some other cause contributed to it.
MG patients with COVID-19 have relatively poor outcomes than the general population with COVID-19. MG patients may have exacerbation of symptoms either due to infection “trigger” or due to drugs such as azithromycin “triggering” symptoms. It is a double-edged sword infection “triggering” MG crises and immunosuppressants leading to increased risk of infection. MG crisis secondary to COVID-19 vaccination has also been reported.[11] MG patients are recommended to get vaccinated at the earliest with adequate monitoring for symptoms exacerbation postvaccination while continuing the practice of COVID-appropriate behavior and masking with extra vigilant social distancing and avoiding public gatherings.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Acknowledgments
To Dr. Sriram Pothapregada, Professor and Head of Department - Pediatrics, IGMC and RI, Puducherry for his critical inputs to the article.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | Županić S, Šitum MP, Majdak M, Karakaš M, Bašić S, Sporiš D. Case series of COVID-19 in patients with myasthenia gravis: A single institution experience. Acta Neurol Belg 2021;121:1039-44.  |
| 2. | Aksoy E, Oztutgan T. COVID-19 presentation in association with myasthenia gravis: A case report and review of the literature. Case Rep Infect Dis 2020;2020:8845844. doi: 10.1155/2020/8845844. |
| 3. | Delly F, Syed MJ, Lisak RP, Zutshi D. Myasthenic crisis in COVID-19. J Neurol Sci 2020;414:116888. |
| 4. | Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, Howard JF, et al. Guidance for the management of Myasthenia Gravis (MG) and Lambert-Eaton Myasthenic Syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci 2020;412:116803. |
| 5. | Vanamoorthy P, Singh GP, Bidkar PU, Mitra R, Sriganesh K, Chavali S, et al. The Neurocritical Care Society of India (NCSI) and the Indian Society of Neuroanaesthesiology and Critical Care (ISNACC) Joint position statement and advisory on the practice of neurocritical care during the COVID-19 pandemic. J Neuroanaesth Crit Care 2020;7:128-39. |
| 6. | Camelo-Filho AE, Silva AM, Estephan EP, Zambon AA, Mendonça RH, Souza PV, et al. Myasthenia gravis and COVID-19: Clinical characteristics and outcomes. Front Neurol 2020;11:1053. |
| 7. | Specialist Pharmacy Service of NHS, UK. How do you Convert an Oral Pyridostigmine or Neostigmine Dose to a Parenteral Neostigmine Dose? Prepared by UK Medicines Information (UKMi) Pharmacists for NHS Healthcare Professionals. Available from: https://www.sps.nhs.uk/. [Last accessed on 2020 Jan 08]. |
| 8. | Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis: An update. J Clin Med 2021;10:1537. |
| 9. | Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7. |
| 10. | Hübers A, Lascano AM, Lalive PH. Management of patients with generalised myasthenia gravis and COVID-19: Four case reports. J Neurol Neurosurg Psychiatry 2020;91:1124-5. |
| 11. | Tagliaferri AR, Narvaneni S, Azzam MH, Grist W. A case of COVID-19 vaccine causing a myasthenia gravis crisis. Cureus 2021;13:e15581. |
|
